de Seze, Jerome
Dive, Dominique
Ayrignac, Xavier
Castelnovo, Giovanni
Payet, Marianne
Rayah, Amel
Gobbi, Claudio
Vermersch, Patrick
Zecca, Chiara
Article History
Received: 13 February 2024
Accepted: 8 March 2024
First Online: 8 April 2024
Declarations
:
: Jerome de Seze has received fees for consultancy, advisory board and clinical trials from UCB, Novartis, Biogen, Merck, Teva, Genzyme/ Sanofi, Roche, Alexion, BMS/Celegene, Janssen, Horizon Therapeutics. Dominique Dive has received fees for consultancy, advisory board and clinical trials from Novartis, Biogen, Merck, Teva, Genzyme/ Sanofi, Roche, Alexion, BMS/Celegene, Janssen. Xavier Ayrignac has received consulting and lecturing fees, travel grants, and unconditional research support from Alexion, Biogen, Genzyme, Janssen, Novartis, Merck Serono, Roche, and Teva Pharma. Giovanni Castelnovo received fees for consulting and speaking from Biogen, Abbvie, Merck, Novartis, Roche, Sanofi Genzyme, Merz, Celgene BMS. Marianne Payet and Amel Rayah are employees of Merck Santé S.A.S., Lyon, France, an affiliate of Merck KGaA. Ente Ospedaliero Cantonale (employer) received compensation for Chiara Zecca’s speaking activities, consulting fees, or grants from Abbvie, Almirall, Biogen Idec, Bristol Meyer Squibb, Lundbeck, Merck, Novartis, Sandoz, Sanofi, Teva Pharma, Roche. CZ is recipient of a grant for senior researchers provided by AFRI (Area Formazione accademica, Ricerca e Innovazione), EOC. Patrick Vermersch received honoraria for contributions to meetings from Biogen, Sanofi-Genzyme, Novartis, Teva, Merck, Roche, Imcyse, AB Science, Ad scientiam and BMS-Celgene, and research support from Novartis, Sanofi-Genzyme and Merck. Ente Ospedaliero Cantonale (employer) received compensation for Claudio Gobbi’s speaking activities, consulting fees, or grants from Almirall, Biogen Idec, Bristol Meyer Squibb, Merck, Novartis, Sandoz, Sanofi, Teva Pharma, Roche.
: This narrative review is based on previously conducted studies and the clinical expertise of the authors in treating patients with RMS. No new clinical studies were performed by the authors. No patient-specific efficacy or safety data were reported. Therefore, institutional review board (IRB)/ethics approval was not required.